FMC (FMC) investor relations material

Strategic review and future direction

• Two parallel tracks: operational turnaround (Plan A) targeting 2026 and a broader strategic review (Plan B) including options up to a sale or merger.

• Active board-level discussions on strategic alternatives, with clarity expected between mid-June and the Q2 call at the end of July.

• Ongoing evaluation of offers and propositions, with a desire to reach a formal direction soon.

Turnaround initiatives and growth drivers

• Four key initiatives: aggressive debt reduction, cost restructuring, Rynaxypyr strategy execution, and commercialization of four new active ingredients.

• Debt paydown goal of $1 billion, with $700 million in active negotiations including the $250 million India business sale and imminent licensing deals.

• Licensing and asset sales prioritized to minimize EBIT impact; further actions may require more difficult trade-offs.

New product pipeline and market potential

• Four new active ingredients expected to drive sales from $300–$400 million in 2026 to $2 billion by 2035, pending regulatory approvals.

• Dodhylex targets rice and potentially broader crops, Isoflex focuses on cereals with EU launch in 2027, rimisoxafen offers dual novel modes of action for resistant weeds, and fluindapyr is ramping up in soybeans and corn.

• Partnerships, such as with Corteva for fluindapyr, are accelerating market adoption.